Literature DB >> 8444857

Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation.

V Ellis1, K Danø.   

Abstract

We have observed that a murine IgG1 monoclonal antibody directed against human urokinase-type plasminogen activator (uPA) greatly potentiates pro-uPA-mediated plasminogen activation. This effect was dependent on the interaction between the immunoglobulin and the kringle domain of pro-uPA and could be competed efficiently by kringle-containing proteolytic fragments of uPA. In addition, the potentiation could also be competed by the lysine analog 6-aminohexanoic acid, an antagonist of plasminogen binding. This unexpected plasminogen binding dependence was found to be due to a carboxyl-terminal lysine residue on the immunoglobulin gamma chain, which by analogy with other proteins represents a potential binding site for plasminogen. Removal of this residue with carboxypeptidase B resulted in a complete abolition of the potentiation. It appears therefore that the potentiatory effect involves a novel mechanism with the antibody acting to provide a specific template for the assembly of a ternary complex involving pro-uPA/uPA and plasminogen, enabling them to interact in a catalytically favorable manner. This interpretation was confirmed by studying the kinetics of plasminogen activation by the complex between active, two-chain uPA and the antibody, which resulted in an overall 50-fold increase in reaction efficiency (kcat/Km), primarily due to a reduction in Km from 20 to 0.1 microM. Pro-uPA activation by plasmin was also accelerated, although to a lesser extent. The potentiation due to complex formation also provides a mechanism for the initiation of this system, dependent only on the low intrinsic proteolytic activity of the zymogen forms. The effects observed here, mediated by ternary complex formation, simulate the effects we have previously observed on assembly of the uPA receptor-mediated cellular plasminogen activation system and may therefore represent a mechanistic model for both its activity and initiation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8444857

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

Authors:  Kenneth A Botkjaer; Sarah Fogh; Erin C Bekes; Zhuo Chen; Grant E Blouse; Janni M Jensen; Kim K Mortensen; Mingdong Huang; Elena Deryugina; James P Quigley; Paul J Declerck; Peter A Andreasen
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

2.  Bound plasminogen is rate-limiting for cell-surface-mediated activation of plasminogen by urokinase.

Authors:  S Namiranian; Y Naito; V V Kakkar; M F Scully
Journal:  Biochem J       Date:  1995-08-01       Impact factor: 3.857

3.  Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells.

Authors:  Sumaira Amir; Naira V Margaryan; Valerie Odero-Marah; Zhila Khalkhali-Ellis; Mary J C Hendrix
Journal:  Cancer Biol Ther       Date:  2005-04-21       Impact factor: 4.742

4.  Tristetraprolin inhibits the growth of human glioma cells through downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor mRNAs.

Authors:  Jinhyun Ryu; Nal Ae Yoon; Yeon Kyung Lee; Joo Yeon Jeong; Seokmin Kang; Hyemin Seong; Jungil Choi; Nammi Park; Nayoung Kim; Wha Ja Cho; Sun Ha Paek; Gyeong Jae Cho; Wan Sung Choi; Jae-Yong Park; Jeong Woo Park; Sang Soo Kang
Journal:  Mol Cells       Date:  2014-12-30       Impact factor: 5.034

5.  The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.

Authors:  Niels Behrendt; Karin List; Peter A Andreasen; Keld Danø
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

6.  A matriptase-prostasin reciprocal zymogen activation complex with unique features: prostasin as a non-enzymatic co-factor for matriptase activation.

Authors:  Stine Friis; Katiuchia Uzzun Sales; Sine Godiksen; Diane E Peters; Chen-Yong Lin; Lotte K Vogel; Thomas H Bugge
Journal:  J Biol Chem       Date:  2013-05-14       Impact factor: 5.157

7.  Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin.

Authors:  V Ellis; K Danø
Journal:  Biochem J       Date:  1993-12-01       Impact factor: 3.857

8.  A CCR2 macrophage endocytic pathway mediates extravascular fibrin clearance in vivo.

Authors:  Michael P Motley; Daniel H Madsen; Henrik J Jürgensen; David E Spencer; Roman Szabo; Kenn Holmbeck; Matthew J Flick; Daniel A Lawrence; Francis J Castellino; Roberto Weigert; Thomas H Bugge
Journal:  Blood       Date:  2015-12-08       Impact factor: 22.113

9.  Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.

Authors:  Gillian E Stillfried; Darren N Saunders; Marie Ranson
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

10.  Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.

Authors:  Juan F Santibanez
Journal:  ISRN Dermatol       Date:  2013-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.